Y. Barekatain

Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism

This study shows that angiogenesis inhibitors enhance the effectiveness of metabolic therapies in gliomas by inducing anaplerotic nutrient stress.

Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner

This study shows that MRTX1133, a KrasG12D inhibitor, reduces early pancreatic lesions and, when combined with immunotherapy, regresses advanced PDAC by enhancing CD8+ T cell activity.

Quantification of phosphonate drugs by 1H-31P HSQC shows that rats are better models of primate drug exposure than mice

The paper quantifies phosphonate drugs using 1H-31P HSQC NMR, showing rats provide better drug exposure models than mice for phosphonate-containing compounds.

Structure-guided microbial targeting of antistaphylococcal prodrugs

This study identifies microbial esterases in Staphylococcus aureus and determines their substrate specificities to guide the design of serum esterase-resistant antistaphylococcal prodrugs.

Targeting host glycolysis as a strategy for antimalarial development.

The paper investigates enolase inhibitors' effects on erythrocytes and their implications for antimalarial therapy by examining red blood cell homeostasis and parasite growth.

Robust detection of oncometabolic aberrations by 1H-13C heteronuclear single quantum correlation in live cells and intact tumors ex-vivo

This paper demonstrates that 1H-13C HSQC NMR can detect oncometabolic aberrations in live cells and tumors without specialized equipment, improving sensitivity and resolution over traditional methods.

Methylthioadenosine is Not Dramatically Elevated in MTAP-Homozygous Deleted Primary Glioblastomas

This paper shows that MTA levels are not significantly elevated in MTAP-homozygous deleted primary human glioblastomas, challenging the clinical relevance of targeting PRMT5 and MAT2A in these tumors.